What Indegene does

Indegene Limited (NSE/BSE: INDGN) is a publicly listed, tech-native life sciences specialist founded in 1998 in Bengaluru, India, with US headquarters in Princeton, NJ, and 18+ offices across North America, Europe, and Asia Pacific. The company orchestrates commercialization for life sciences organizations across the full value chain, from clinical development through medical affairs to commercial operations, serving 19 of the world's top 20 biopharmaceutical enterprises plus emerging biotech and global medical device manufacturers.

The company operates a platform-plus-services model. Its service suites span Enterprise Commercial Solutions, Enterprise Medical Solutions, Enterprise Clinical Solutions, Technology Solutions, and Omnichannel Activation Solutions, delivered through a global delivery model anchored in India and complemented by regional consulting offices. Its proprietary technology stack is organized around the NEXT platform family (NEXT MLR Review Automation, NEXT Regulatory Submissions Planning, NEXT Medical Writing Automation, NEXT Content Management, NEXT Safety, NEXT Customer Data Management, NEXT Clinical Trials, NEXT Workflow Management, and NEXT Regulatory Intelligence and Planning) and the Cortex enterprise-grade Generative AI platform, which combines 25+ years of codified life sciences domain expertise with multi-agent orchestration, an LLM-agnostic architecture, and a Knowledge Engineering Interface for SMEs. Supporting platforms include Invisage (HCP omnichannel, backed by 2M HCPs and 200M interactions), Connected Content Ecosystem, and Connected Commercial, integrated with Veeva, Salesforce, Medidata, Oracle, Adobe, AWS, Google Cloud, and Microsoft.

Indegene generates revenue through professional services engagements with biopharma clients, technology platform licensing/subscription (Cortex, NEXT platforms), and managed services with outcome-based pricing (Connected Content Ecosystem). Pricing is quote-based and not publicly disclosed. The company has been an aggressive inorganic builder: notable acquisitions include CultHealth (2022), DT Associates (2019), Trilogy Writing & Consulting (2024), M J L (2025), Cake Kommunikation (announced Nov 2025), Cake Health (Feb 2026), and BioPharm (2026). FY2025-26 consolidated revenue reached Rs 3,510.50 crore (~USD 415M), growing 23.64% YoY in INR (18.2% in USD). Net profit was Rs 401.10 crore, with EBITDA margin temporarily compressed by acquisition-related costs. Carlyle Group exited its 10.2% stake in June 2025; Premji Invest and Societe Generale acquired positions, and the board has been reinforced with US pharma and PE operators.

Name

Indegene

Legal name

Indegene Limited

Website

https://indegene.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Indegene is a publicly listed tech-native life sciences specialist that delivers AI-enabled commercialization, medical, clinical, and regulatory services and platforms to 19 of the world's top 20 biopharmaceutical companies and emerging biotechs globally.

Ownership category

akta.pro rank

Product category

Life Sciences Commercialization Services and Technology Platforms

akta.pro primary industry

Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)

akta.pro secondary industries

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Medication Pricing, Copay Assistance & Patient Financial Support Tools (HLACAKAN)

Keywords

• Life sciences commercialization
• Biopharmaceutical technology services
• Medical regulatory operations
• Clinical trial patient recruitment
• Omnichannel pharmaceutical marketing

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices18 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Enterprise Commercial Solutions: Services revenue from improving commercial operations effectiveness and efficiency, including omnichannel activation, content services, marketing operations, data and analytics, and technology transformation for biopharmaceutical companies. This is the largest revenue segment.
2. Enterprise Medical Solutions: Revenue from regulatory operations, pharmacovigilance, medical affairs, medical information, medical writing, pricing and market access, HEOR, and safety services. Includes technology-enabled services with AI-powered platforms.
3. Enterprise Clinical Solutions: Revenue from clinical trial services including patient recruitment, biometrics, real-world data solutions, and consulting. Leverages proprietary technology platforms and databases.
4. Omnichannel Activation Solutions: Revenue from digital rep equivalence, customer experience journeys, omnichannel strategy, and the Invisage platform. Augments pharmaceutical sales forces with AI-driven digital capabilities.
5. Technology Solutions: Revenue from platform services, digital engineering, AI and deep tech implementation, and data analytics transformation. Includes licensing of proprietary platforms like Cortex, NEXT MLR, and NEXT Regulatory Submissions.
6. Connected Content Ecosystem: AI and platform-driven approach to unify content value chain in life sciences. Delivered as managed services with outcome-based pricing models.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Indegene is a tech-native life sciences commercialization specialist that combines 25+ years of domain expertise with proprietary AI-driven platforms (Cortex, NEXT MLR, NEXT Regulatory, NEXT Medical Writing, NEXT Safety, Invisage) to deliver commercial, medical, regulatory, and clinical services plus technology platforms to biopharmaceutical companies, emerging biotech, and medical device manufacturers. Its offerings span patient and HCP engagement, omnichannel activation, content supply chain automation, pharmacovigilance, regulatory submissions, medical writing, clinical trial recruitment, and end-to-end commercialization infrastructure.

Product overview

Indegene is a tech-native, life sciences commercialization specialist operating a platform-plus-services model. Its portfolio spans Enterprise Commercial, Medical, and Clinical Solutions (service suites), proprietary NEXT Technology Platforms (NEXT MLR Review Automation, NEXT Regulatory Submissions Planning, NEXT Medical Writing Automation, NEXT Content Management, NEXT Safety, NEXT Customer Data Management, NEXT Clinical Trials, NEXT Workflow Management, NEXT Regulatory Intelligence and Planning), and the Cortex Generative AI platform. Key sub-brands and acquired companies include CultHealth (full-service marketing agency), Trilogy Writing & Consulting (medical writing), and MME (pricing/market access advisory). Indegene's platforms are integrated with third-party EDC systems (Medidata Rave, Veeva Vault, Oracle Inform, Viedoc, Medrio), Veeva CRM (Certified Partner), Salesforce, Tealium, Adobe, AWS, Google Cloud, Microsoft, and Acquia. The company serves biopharmaceuticals, emerging biotech, and medical devices across a global delivery model.

Differentiator

Problem solved

Functional benefit

Brands

• CultHealth: Full-service marketing agency focused on healthcare marketers, developing customized strategies, creative campaigns, and innovative tactics
• Trilogy Writing & Consulting
• MME
• Indegene Cortex
• NEXT Medical Writing Automation
• NEXT MLR Review Automation
• Invisage

Products and services

• Cortex Indegene's enterprise-grade Generative AI platform purpose-built for the life sciences industry. Cortex combines over 25 years of subject matter expertise with advanced knowledge engineering and fit-for-purpose AI agents within a flexible, multi-agent orchestration framework that is LLM-agnostic, enabling customers to scale high-value use cases across MLR review, medical writing, content supply chain, and regulatory submissions.
• NEXT MLR Review Automation Proprietary platform powered by advanced Agentic AI that transforms the end-to-end Medical-Legal-Regulatory (MLR) review process by streamlining workflows, reducing review cycles, minimizing rework, ensuring global and local compliance, and providing intelligent content suggestions and automated reference anchoring for life sciences content.
• NEXT Regulatory Submissions Planning AI-powered planning platform bringing together deep regulatory expertise and planning capabilities to help life sciences companies deliver accurate, compliant, and on-time submissions across health authorities worldwide, predicting risks, adapting to changing regulations, prioritizing submissions, and cutting timelines by up to 40%.
• NEXT Medical Writing Automation Generative AI-powered end-to-end medical and regulatory writing platform that streamlines complex workflows through intelligent automation, supporting protocols, Clinical Study Reports, aggregate reports, and patient narratives with AI-driven data extraction, trend analysis, and traceability for life sciences documentation.
• Invisage Integrated hybrid omnichannel platform bringing together data, AI-driven scientific modeling, and strategic insights to predict results-generating omnichannel communications for engaging healthcare professionals, built on data spanning 2 million HCPs and 200 million HCP interactions.
• Next Commercial Content Authoring (NCCA) GenAI-powered content authoring platform that empowers teams to create, adapt, and scale content efficiently, producing channel-agnostic modules and derivative assets like emails, banners, and e-details with speed, precision, compliance, and cost savings.
• Connected Content Ecosystem AI and platform-driven approach that unifies the content value chain from planning, design, and approval through production, delivery, and optimization for life sciences, powered by Generative AI with a 10:90 human-to-tech ratio in production, achieving over 90% template usage and reducing manual effort by 80% in the approval phase.
• Connected Commercial Integrated ecosystem transforming commercial operations by unifying content and campaign management where campaign performance informs content creation, blending integrated brand and production agency capabilities with a unified medico-promotional center of excellence for biopharmaceutical clients.
• NEXT Content Management Platforms Suite of NLP, ML, and machine vision platforms trained for life sciences content modularization, metadata generation, content comparison, document lineage mapping, and new content creation with high automation requiring human supervision for quality assurance.
• NEXT Regulatory Intelligence and Planning Suite of platforms for automatic monitoring of guidelines published by regulatory agencies (US FDA, EMA), and for optimizing resource allocation to prioritize submission timelines of regulatory documents across markets to maximize the business potential of new launches.
• NEXT Safety Platform Platform that automates the conversion of unstructured data to structured data for pharmacovigilance case intake and processing, disrupting the headcount-intensive adverse event case intake and conversion into structured fields for safety databases.
• NEXT Customer Data Management and Analytics Fit-for-purpose data ecosystem enabling nimble data integration from CRM, sales, marketing, channel, prescription, and real-world data (medical claims, EMRs) into analytics-ready datasets, powering sales forecasting, omnichannel targeting, segmentation, cohort builders, and next best action recommendations.
• NEXT Clinical Trials Platform Easily configurable platform integrating HEOR, medical claims, genomics, lab and other data sources to model disease states and progression using graph-based predictive algorithms; includes patient cohort builder to accelerate recruitment and enable evidence-based clinical trial design.
• NEXT Workflow Management Platform Platform with in-built workflows catering to functions across the life sciences commercialization continuum from regulatory content development to global product labelling, digital content development, and omnichannel campaign design and execution, enabling global collaboration and eliminating handovers.
• Enterprise Commercial Solutions Suite of commercial operations services for biopharmaceutical companies including patient services, strategy and consulting, creative and content services, marketing operations, data and analytics, technology transformation, and Veeva Services (Certified Partner for CRM, Vault PromoMats, Approved Email, CLM, Align, Events, Engage).
• Enterprise Medical Solutions Suite of medical operations services including omnichannel medical strategy, intelligent MLR solution, medical information and communication, safety and pharmacovigilance, pricing and market access (MME), medical writing (including Trilogy Writing), regulatory operations, publishing and submissions, labeling and artwork, learning and development, HEOR, digital medical equivalence, and Generative AI guidance.
• Enterprise Clinical Solutions Suite of clinical operations services including digital patient recruitment and engagement (leveraging ~1.2 million HCP database), biometrics for clinical trials, real-world data for clinical trials (85+ million patient records processed), and consulting services, with EDC partnerships spanning Medidata Rave, Veeva Vault, Oracle Inform, Viedoc, and Medrio.
• Technology Solutions IT transformation services for life sciences including platform services, digital engineering, AI and deep tech, and data and analytics transformation, integrating with best-of-breed technology platforms (Veeva, Salesforce, Tealium, Adobe, AWS, Google Cloud, Microsoft) to reduce implementation friction.
• Agency Of Scale Fractional access model that inverts the 80/20 agency spend ratio by combining the strategic creative resources of tier-1 advertising agency (CultHealth) with at-scale production capabilities of Enterprise Commercial Solutions, delivered through a distributed global model augmented by data, AI, and medical expertise.
• Omnichannel Activation Solutions Omnichannel activation services including Digital Rep Equivalence solution that leverages proprietary HCP data to augment client data and deliver actionable micro-segments activated through well-orchestrated digital touchpoints, comparing physician digital and prescription behavior at the individual level to deliver impact comparable to in-person interactions.
• CultHealth (An Indegene Company) Full-service healthcare marketing agency, an Indegene company, focused on the unique needs of healthcare marketers, developing customized strategies, creative campaigns, and innovative tactics spanning national advertising, DTC and social media campaigns, mobile CRM programs, and experiential marketing for physicians and patients.
• Trilogy Writing & Consulting GmbH (An Indegene Company) Medical writing services company with over 22 years of experience providing medical writing to biopharmaceutical and medical devices industry; acquired to combine in-depth expertise with Indegene's core capabilities for medical writing at scale.
• MME (An Indegene Company) Pricing, reimbursement, and market access advisory firm acquired by Indegene that specializes in global and single country gross-to-net price planning, payer research, dossier development, value story decks, and pricing benchmarks across therapeutic areas.

Quantifiable outcome

• Reduces time-to-patient-insights by 80%
• +9 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability16 records

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• Cingulate Inc.coreStrategic or Co-development Partner · 10 November 2025Cingulate partnered with Indegene to build commercial infrastructure for the potential launch of CTx-1301 (once-daily ADHD medication). Indegene is supporting commercial infrastructure development targeting the over $23 billion global ADHD market. The partnership was formed coinciding with FDA acceptance of Cingulate's NDA for CTx-1301 with a PDUFA date of May 31, 2026.
• FAST IndiacoreStrategic or Co-development Partner · 2 July 2025FAST India (Foundation for Arts, Sciences & Technology) announced a strategic partnership with Indegene to accelerate biotech innovation in India. The partnership focuses on expanding research collaboration between academia and industry. FAST India is a non-profit organization aiming to position India among the world's top three science and technology nations within the next decade through translational science and industry-academia partnerships.
• VeevacoreTechnology or IntegrationVeeva Certified Partner providing services across Veeva CRM, Vault PromoMats, Veeva Approved Email, Veeva CLM, Veeva Align, Veeva CRM Events Management, and Veeva Engage. Indegene has over 149 Veeva certified professionals and was the first partner selected for Veeva's Digital Factory Accelerator Program.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Inizio: Global life-sciences commercialization platform combining consulting, medical communications, and patient solutions. Directly comparable to Indegene's full-stack clinical, medical, and commercial value chain coverage.
• ZS Associates: Global management and technology consulting firm with a deep life-sciences commercial practice (sales, marketing, analytics, and AI). Comparable to Indegene in serving top-20 biopharma with data-driven commercial transformation and analytics-led decisioning.
• Trinity Life Sciences: Life-sciences commercial strategy and insights firm offering consulting, analytics, and AI-enabled commercialization support. Closely comparable to Indegene's enterprise commercial and omnichannel activation offerings.
• Avalere Health: Advisory and services firm focused on market access, medical affairs, and commercial strategy for biopharma. Overlaps with Indegene's MME (pricing/market access) and Enterprise Medical Solutions businesses.
• Eversana: Independent commercialization services partner for life sciences spanning field solutions, market access, and patient services. Direct overlap with Indegene's Enterprise Commercial Solutions, and notably a prior employer of Indegene SVP Peter Marchesini.
• Fishawack Health: Global life-sciences commercialization and medical communications agency serving biopharma across medical affairs, marketing, and omnichannel. Highly comparable to Indegene's CultHealth and Enterprise Medical Solutions practices.

Broad incumbents

• IQVIA: Global leader in clinical research, real-world evidence, and life-sciences technology/analytics. Overlaps with Indegene's Enterprise Clinical Solutions and RWD/biometrics capabilities but operates at vastly greater scale across the full drug development lifecycle.
• ICON plc: Major global CRO with growing digital and commercial services. Competes with Indegene's clinical trial services, particularly biometrics, EDC, and patient recruitment, though ICON's core focus is clinical operations.
• Cognizant Life Sciences: Global IT services giant with a dedicated life-sciences digital practice covering commercial, clinical, and digital transformation. Comparable in technology-led life-sciences services, but with much broader industry coverage and larger delivery footprint.

Others

• Veeva Systems: Life-sciences cloud platform provider (CRM, Vault, etc.) with which Indegene is a Certified Partner (149+ certified professionals) and was the first partner in Veeva's Digital Factory Accelerator Program. Not a direct competitor but the underlying platform Indegene implements and extends for commercial operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries8 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indegene